GlassScriptPhysician profile
Marvin Matta Rivera
NPI 1629357488
$7,817.84
in general payments reported to CMS, 2019-2025
38 companies · $3,266 in 2025
The $3,266 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $125 · 2021: $174 · 2022: $626 · 2023: $1,313 · 2024: $1,636 · 2025: $3,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,948 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,947.54 |
| Education | $267.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,064.31 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Pharmaceuticals, INC | $931.35 | 2022-2025 | Erleada, Rybrevant, Darzalex |
| Abbvie INC. | $639.13 | 2019-2025 | |
| Pbg Puerto Rico LLC | $545.79 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $500.75 | 2019-2025 | Opdivo, Breyanzi, Reblozyl |
| Merck Sharp & Dohme LLC | $488.91 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $476.66 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Eli Lilly Export S.A. Puerto Rico Branch | $384.17 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $367.49 | 2019-2025 | Xgeva, Kyprolis, Lumakras |
| Janssen Biotech, INC. | $345.98 | 2021-2025 | Erleada, Darzalex |
| Genzyme Corporation | $312.30 | 2019-2025 | |
| Bayer Puerto Rico INC. | $212.14 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Regeneron Healthcare Solutions, INC. | $193.32 | 2023-2025 | Libtayo |
| Tempus Ai, INC | $169.79 | 2025 | Xt Cdx |
| Incyte Corporation | $162.55 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Matta Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.